Skip to main content
Clinical Trials/JPRN-UMIN000003237
JPRN-UMIN000003237
Completed
Phase 3

A phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical stage II/III squamous cell carcinoma of the anal canal (JCOG0903, SMART-AC) - A phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical stage II/III squamous cell carcinoma of the anal canal (JCOG0903, SMART-AC)

Japan Clinical Oncology Group(JCOG)0 sites71 target enrollmentFebruary 23, 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
anal canal caner
Sponsor
Japan Clinical Oncology Group(JCOG)
Enrollment
71
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 23, 2010
End Date
February 23, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japan Clinical Oncology Group(JCOG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy 2\) Patients requiring the administration of phenytoin or warfarin potassium 3\) Pregnant or lactating women or women of childbearing potential 4\) Psychosis 5\) Patients requiring systemic steroids medication 6\) Serum HBs antigen positive 7\) Anti\-HIV antibody positive 8\) Uncontrollable diabetes mellitus or administration of insulin. 9\) Uncontrollable hypertention 10\) Unstable angina, heart failure, or with a history of myocardial infarction within 6 months. 11\) Interstitial pneumonia, fibroid lung, or severe emphysema 12\) Active bacterial or fungous infection 13\) fever over 38 degrees centigrade

Outcomes

Primary Outcomes

Not specified

Similar Trials

A phase I/II trial of chemoradiotherapy... | Clinical Trial